跳转至内容
Merck

V5514

Sigma-Aldrich

Anti-Vasopressin V2 Receptor antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

登录查看公司和协议定价


About This Item

MDL號碼:
分類程式碼代碼:
12352203
NACRES:
NA.41

生物源

rabbit

品質等級

共軛

unconjugated

抗體表格

affinity isolated antibody

抗體產品種類

primary antibodies

無性繁殖

polyclonal

形狀

buffered aqueous solution

物種活性

human

技術

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 3 μg/mL using human kidney

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−20°C

基因資訊

human ... AVPR2(554)
mouse ... Avpr2(12000)
rat ... Avpr2(25108)

免疫原

Synthetic peptide corresponding to the N-termal extracellular domain of human vasopressin V2 receptor. The immunizing peptide has 67% homology with the rat and mouse gene.

應用

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunohistochemistry (1 paper)

生化/生理作用

Vasopressin V2 receptor is a G-protein-coupled receptor that binds to the peptide hormone arginine vasopressin produced by posterior pituitary gland. The V2 receptor stimulates the production of cyclic AMP, controls the water reabsorption and salt balance by the kidneys. Antagonists to the V2 receptor have applications in the treatment of congestive heart failure, hypertension, hyponatremia and excessive water retention.

外觀

Solution in phosphate buffered saline containing 0.1% sodium azide.

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Natasha Tatiana Sobol et al.
Experimental and therapeutic medicine, 21(6), 566-566 (2021-04-15)
Osteosarcoma is the most prevalent primary bone malignancy. Due to its high aggressiveness, novel treatment strategies are urgently required to improve survival of patients with osteosarcoma, especially those with advanced disease. Desmopressin (dDAVP) is a widely used blood-saving agent that
[Human recombinant alpha-2b interferon (Introna). Intralesional treatment of therapy-resistant condylomata acuminata].
C S Petersen et al.
Ugeskrift for laeger, 149(24), 1594-1595 (1987-06-08)
Juan Garona et al.
Clinical & experimental metastasis, 33(6), 589-600 (2016-05-06)
[V(4)Q(5)]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V(4)Q(5)]dDAVP inhibits angiogenesis and metastatic progression
Abeda Jamadar et al.
International journal of molecular sciences, 23(14) (2022-07-28)
Vasopressin type-2 receptor (V2R) is ectopically expressed and plays a pathogenic role in clear cell renal cell carcinoma (ccRCC) tumor cells. Here we examined how V2R signaling within human ccRCC tumor cells (Caki1 cells) stimulates stromal cancer-associated fibroblasts (CAFs). We
Shuai Mu et al.
Molecules (Basel, Switzerland), 19(2), 2694-2706 (2014-02-26)
Twenty-one non-peptide substituted desloratadine class compounds were synthesized as novel arginine vasopressin receptor antagonists from desloratadine via successive acylation, reduction and acylation reactions. Their structures were characterized by 1H-NMR and HRMS, their biological activity was evaluated by in vitro and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门